BioPharma
-
Which biopharma startups will compete at INVEST Pitch Perfect?
AI, therapeutics for autoimmune diseases, automation for biomedical research and oncology are among the areas of interest for the finalists in the biopharma track scheduled for day two of the conference.
-
Artificial Intelligence, BioPharma
Relay Therapeutics pays $85M for startup with a new AI tech for drug discovery
Relay Therapeutics has its own technology that applies artificial intelligence and machine learning techniques to drug discovery. Its $85 million acquisition of ZebiAI gives it another technology that applies ML to DNA-encoded libraries and predicts the small molecules with the potential to drug proteins.
-
How Presbyterian Is Using Digital Health Tools to Address Pandemic Challenges
Timing is everything. In the case of Presbyterian Healthcare Services, its adoption of the Bright.MD platform in 2017 to facilitate telehealth appointments was fortuitous. Read now to learn more.
-
StartUPDATES: New developments for healthcare startups
Serimmune is enrolling more than 2,000 participants in a clinical study designed to understand the human immune response to the virus that causes Covid-19. Also, news from Legacy, Tomorrow Health, and more.
-
Merck’s Covid-19 drug R&D falls short twice in treating hospitalized patients
Merck is discontinuing work on one Covid-19 drug for treating hospitalized patients after the FDA said it needs more clinical data. Another Merck drug candidate is moving forward only in outpatient testing after independent clinical trial observers concluded the antiviral was unlikely to help those in the hospital.
-
Thermo Fisher’s $21B deal for PPD gives it missing piece in drug development cycle
Thermo Fisher Scientific sells laboratory equipment used in drug research and it also offers manufacturing services for experimental and commercialized drugs. By acquiring PPD, Thermo Fisher says it will gain capabilities in the growing global market of clinical trial services.
-
Amylyx Pharma’s ALS drug needs a Phase 3 study to support FDA submission
Amylyx’s ALS drug met the goals of a mid-stage study, paving the way for regulatory submissions in Europe and Canada. But the FDA is requiring data from a larger Phase 3 clinical trial and that study is slated to begin later this year.
-
BioPharma, Health IT, Hospitals, Physicians, sponsored content, Sponsored Post, SYN
How are healthcare organizations shifting to digital documents?
In order to gain insight into how organizations are thinking about digitizing medical documents and the strategy behind those decisions, we’re conducting a brief survey of the MedCity News audience and will publish a report based on this survey’s findings.
-
Cancer biotech Tango Therapeutics picks a SPAC as its IPO dance partner
Tango Therapeutics’ SPAC merger will infuse the biotech with $353 million to fund clinical trials for its cancer drugs based on synthetic lethality. Tango’s lead program is on track to reach the clinic next year.
-
FDA & CDC “pause” J&J Covid-19 vaccine to launch inquiry into rare blood clot cases
Blood clots found in six women given Johnson & Johnson’s Covid-19 vaccine have led federal health officials to recommend a pause on dosing with that shot. A CDC advisory committee on vaccine practices is meeting Wednesday to review the cases, which appear similar to cases observed in Europe with AstraZeneca’s vaccine.
-
Fruit Street Health launches employer advisory board to manage healthcare costs with digital health
The goal of Fruit Street Labs is to form a collaborative relationship between Fruit Street and employers so that they can jointly develop telemedicine and digital health solutions that address rising healthcare costs and chronic disease in employee populations.
-
Cellino Biotech developing tech to help scale stem cell therapies
Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen talked about the formation of the company and its goal to make stem cell therapies accessible for patients.
-
3 changes coming to drug pricing
No matter if Democrats or Republicans are running the show in Washington, here are three solid bets for pharma companies to plan for in the changing drug-pricing landscape
-
Biotech startup Repertoire adds $189M to expand array of immune medicines
With two cancer programs already making progress, Repertoire Immune Medicines will use the Series B financing to expand its immune synapse research to autoimmune disorders and infectious disease. CEO John Cox said his startup’s approach could advance immune medicines beyond the scope of currently available therapies.
-
Covid-19 was a lightning rod for life science deals last year. What investment trends are taking shape in 2021?
Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, is bullish that the momentum will continue, particularly with investment trends focused on pain points amplified by the Covid-19 pandemic, from diagnostics development to supply chain management.
-
Regeneron, Roche injectable antibody drug shows efficacy in preventing Covid-19
A Regeneron Pharmaceuticals antibody cocktail currently authorized for treating Covid-19 now has additional clinical data showing it reduces the risk of infection spread. The drug developer, along with partner Roche, plan to ask regulators to expand the drug’s authorization to include disease prevention.
-
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy
Sanofi, which already has messenger RNA R&D alliances with other companies, paid $160 million up front to acquire preclinical startup Tidal Therapeutics. The pharma giant said Tidal’s mRNA approach could lead to an off-the-shelf CAR-T therapy.
Promoted
Bristol Myers Squibb SVP Ho Sung Cho highlights pioneering work with protein degradation in support of drug development
In a podcast with MedCity News, Cho talked about the company’s profile in the San Diego life science ecosystem, the need to fail fast and frequently in the early stages of drug development and the work BMS is doing to combat Covid-19.
Promoted
How are healthcare organizations shifting to digital documents?
In order to gain insight into how organizations are thinking about digitizing medical documents and the strategy behind those decisions, we’re conducting a brief survey of the MedCity News audience and will publish a report based on this survey’s findings.
